Chong Kun Dang Pharmaceutical Corp.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
A Study to Compare PK, PD and Safety of CKD-382 in Healthy Subjects
Phase 1
- Conditions
- GERD
- Interventions
- Drug: CKD-382(formulation I)Drug: CKD-382(formulation II)Drug: D026
- First Posted Date
- 2021-01-11
- Last Posted Date
- 2021-01-11
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 48
- Registration Number
- NCT04703374
- Locations
- 🇰🇷
Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of
Efficacy and Safety of Sirolimus Plus CNI Compared With MMF Plus CNI in ABO-i Kidney Transplant Recipients.
Phase 4
Not yet recruiting
- Conditions
- Kidney Transplantation
- Interventions
- First Posted Date
- 2021-01-08
- Last Posted Date
- 2021-01-08
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 158
- Registration Number
- NCT04700709
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(2)
Phase 1
Completed
- Conditions
- Hypertension and Dyslipidemia
- Interventions
- Drug: CKD-386Drug: D013, D326, D337
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 62
- Registration Number
- NCT04694989
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of CKD-388 in Healthy Subjects
Phase 1
- Conditions
- Chronic Hepatitis b
- Interventions
- Drug: D418 Tab.Drug: CKD-388 Tab.
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 56
- Registration Number
- NCT04676893
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fasting Conditions
Phase 1
- Conditions
- Cardiovascular Diseases
- Interventions
- Drug: Reference drugDrug: Test drug 1Drug: Test drug 2
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2020-12-21
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 24
- Registration Number
- NCT04678388
- Locations
- 🇰🇷
Central Hospital, Gyeonggi-do, Siheung-si, Korea, Republic of
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386
Phase 1
Completed
- Conditions
- Hypertension and Dyslipidemia
- Interventions
- Drug: CKD-386Drug: D012, D326, D337
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2021-07-07
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 66
- Registration Number
- NCT04673864
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
A Clinical Study to Evaluate the Safety and Pharmacokinetics of CKD-344
Phase 1
- Conditions
- Anticoagulant
- Interventions
- Drug: Lixiana(D006)Drug: CKD-344
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 50
- Registration Number
- NCT04673695
- Locations
- 🇰🇷
Yook-Hwan Noh, Seoul, Korea, Republic of
A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-845
Phase 1
Completed
- Conditions
- Hypogonadism
- Interventions
- Drug: D309Drug: CKD-845
- First Posted Date
- 2020-12-17
- Last Posted Date
- 2022-09-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 47
- Registration Number
- NCT04673682
- Locations
- 🇰🇷
Jeonbuk University Hospital, Jeonju, Jeonbuk, Korea, Republic of
The Purpose of Study is to Evaluate the Safety, Pharmacokinetics and Anti-tumor Effects of CKD-702 in Patients With Advanced or Metastatic Non-small Cell Lung Cancer Who Failed to Standard Therapy
Phase 1
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Drug: CKD-702
- First Posted Date
- 2020-12-16
- Last Posted Date
- 2020-12-16
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 74
- Registration Number
- NCT04667975
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-348
Phase 1
Completed
- Conditions
- Hypertension and Dyslipidemia
- Interventions
- Drug: CKD-348Drug: CKD-828, D097, D337
- First Posted Date
- 2020-12-09
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 70
- Registration Number
- NCT04660370
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath